Navigation Links
Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
Date:8/11/2011

eiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days. NUEDEXTA is contraindicated in patients with a known hypersensitivity to its components.

NUEDEXTA may cause serious side effects, including possible changes in heart rhythm. NUEDEXTA is contraindicated in patients with a prolonged QT interval, congenital long QT syndrome or a history suggestive of torsades de pointes, in patients with heart failure as well as patients with, or at risk of, complete atrioventricular (AV) block, unless the patient has an implanted pacemaker.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk of QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation of QT interval should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions in patients taking NUEDEXTA are diarrhea, dizziness, cough, vomiting, weakness, swelling of feet and ankles, urinary tract infection, flu, elevated liver enzymes, and flatulence. NUEDEXTA may cause dizziness. Precautions to reduce the risk of falls should be taken, particularly for patients with motor impairment affecting gait or a history of falls.

Patients should take NUEDEXTA exactly as prescribed. Patients should not take more than 2 capsules in a 24-hour period, make sure that there is an approximate 12-hour interval between doses, and not take a double dose after they miss a dose.

These are not all the risks from use of NUEDEXTA. For additional important safety information about NUEDEXTA, please see the full Prescribing Information at www.NUEDEXTA.com.

AVANIR™ and NUE
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... Md. , Aug. 19, 2014  Northwest Biotherapeutics ... company developing DCVax® personalized immune therapies for solid tumor ... offering announced last Thursday, August 14, 2014, has closed.  ... are convertible at $7.30 per share of common stock.  ... months, to purchase up to an additional 30% of ...
(Date:8/19/2014)... YORK , Aug. 19, 2014  As ... around the country, Bernstein Liebhard LLP notes that ... can choose between a number of options that ... dangerous surgical instrument. According to a report published ... th , these options include a mini-laparotomy and ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 2NW BIO COMPLETES THE CLOSING OF ITS $17.5 MILLION CONVERTIBLE NOTE OFFERING 3As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 Doctors at the ... to wipe out mesothelioma in laboratory mice by injecting them ... just posted details of the study on its website. ... Scientists with Hong Kong University’s AIDS Institute of Microbiology created ... 1” or PD-1. By altering DNA, the vaccine is designed ...
(Date:8/20/2014)... City, New Jersey (PRWEB) August 20, 2014 ... in meeting the needs of an estimated tens of ... introduction of the new Bill A3525—a bill that would ... patients to grow their own cannabis—earlier this summer by ... horticultural training for medicinal quality marijuana is growing. , ...
(Date:8/20/2014)... August is Children’s Eye Health and Safety ... eye health and safety for their children and have ... that must be checked for, according to Sharon Kleyne, ... radio show, is pediatric dry eye. With computer use ... is becoming a very real concern to ophthalmologists. , ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hope For ... Give Hope® Celebration to be hosted in Washington, DC ... Navy Club. This signature event honors the courage of ... of the fallen. Proceeds from the Got Heart, Give ... national nonprofit dedicated to restoring a sense of self, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Building ... healthcare, Jvion successfully predicted stage iii and iv ... in some situations, approached 90%. A company spokesperson ... achieved in commercial or academic settings. The resulting ... all types of hospital-acquired conditions to help providers ...
Breaking Medicine News(10 mins):Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 2Health News:August is Children’s Eye Health Month, Exams Must Check for Pediatric Dry Eye 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2
... The findings might boost understanding of the disease generally, ... The adult children of people with the rarer, inherited ... new study to better understand the biology of the ... biological parent diagnosed with a known genetic mutation causing ...
... 28 /PRNewswire-Asia/ -- CCID Consulting, China,s leading,research, consulting and ... listed in Hong Kong (Hong Kong Stock Exchange:,HK08235), recently ... , In 2007, ... an increase,in health awareness, which in turn drove the ...
... MD, noted medical researcher and women,s health practitioner, has spoken out ... well as other oral bisphosphonates such as Boniva, Actonel, and Fosamax. ... ... Susan Lark, MD , noted medical researcher and women,s health ...
... Africa, Nov. 27 20 top international,and local companies ... Awards Banquet held tonight at the Michelangelo Hotel in ... and innovation,across a variety of sectors. , ... , The awards ...
... after its use was banned, statistics show that nearly 4,000 people in the ... , ... Manchester,UK (PRWEB) November 27, 2008 -- On 24th November 1999, the Government,s ... statistics show that nearly 4,000 people in the UK die each year from ...
... care nurses are considering quitting in the next year ... Melbourne study. , The study, conducted by the Centre ... and the Australian Nursing Federation finds Victoria,s registered nurses ... not committed to their workplace. , It cites excessive ...
Cached Medicine News:Health News:Study Recruiting From Alzheimer's-Prone Families 2Health News:CCID Consulting Discusses China's Medical Equipment Market 2Health News:CCID Consulting Discusses China's Medical Equipment Market 3Health News:CCID Consulting Discusses China's Medical Equipment Market 4Health News:CCID Consulting Discusses China's Medical Equipment Market 5Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 2Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 3Health News:Susan Lark, MD Speaks Out Against the Newest Osteoporosis Drug, Reclast 4Health News:Frost & Sullivan Recognises Best-in-Class Innovators 2Health News:Frost & Sullivan Recognises Best-in-Class Innovators 3Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 2Health News:Nine Year Ban Fails to Eradicate Asbestos Related Diseases 3Health News:Aged care workers to leave industry en masse due to stress, warns University of Melbourne study 2
... versatile new test providing the broadest range ... The Multi-Target Stereo test can be used ... stereopsis, visual attention, form and depth perception, ... includes a pair of high quality reversible ...
... stereo tests provide accurate measurement of ... choice of polarized glasses. The original ... slipped into a thin plastic frame ... includes Richmonds new P/N 4465 Polycarbonate ...
Comes with seven test plates. Red and green glasses filters are mounted in two frames, one for adults and one for children. Suitable for testing very small children as well as adults....
Lumicon 48 mm red filter....
Medicine Products: